Parenteral Manual

Chorionic gonadotropin

Disclaimer: Official controlled document is the CHEO online copy. It is the responsibility of user to ensure that any paper copy version is the same as the online version before use.

Alternate Name(s): 
Hormonal agent- Gonadotropin - NON-CYTOTOXIC HAZARDOUS
Original Date: 
August 2005
Revised Date: 
June 2015
  • Gonadotropin for various male and female hormone deficiencies
  • Prepubertal cryptochidism
  • Hypogonadotropic hypogonadism
  • Habitual abortion
  • Functional sterility in females
Reconstitution and Stability: 
  • Unreconstituted vial stored at room temperature
  • Stable in fridge for 30 days after reconstitution
  • Reconstitute with 10 mL diluent provided by the manufacturer

- Solutions Compatible: diluent provided by the manufacturer

- Additives/Above Cassette Compatible: no information

- Y-site Compatible: no information

- Incompatible: DO NOT mix with other drugs


(For approved routes of administration by nursing personnel, refer to Policy for the Administration of Intravenous Medications.)

IV Push


IV Intermittant Infusion


IV Continuous Infusion NO

(For neonatal dosages, refer to Neonatal IV Drug Manual.)


  • Individualized: See product monograph (there are many variations of the dosage regimen)
  • Prepubertal cryptochidism: 1000-5000 units 2-3 times/week for 3 weeks or
                                               5000 units every 2nd day for 4 injections or
                                               1000-2000 units/m2/dose 3 times/week for 3 weeks
  • Hypogonadotropic hypogonadism:  500-1000 units 3 times/week for 3 weeks, followed by the same dose twice weekly for 3 weeks
Potential hazards of parenteral administration: 
  • Pain at injection site
  • Headache, irritability, depression, fatigue, edema, precocious puberty, gynecomastia, premature closure of epiphyses
  • Discontinue if vaginal bleeding occurs
  • Treatment for cryptochidism may produce precocious puberty; may be indication to discontinue treatment
  • Contraindicated in androgenic neoplasms
  • May cause fluid retention- use with caution in cardiac diseases, migraine or epilepsy

The information contained on this website is provided for informational purposes only, as a guide to assist physicians, nurses and other healthcare providers in deciding on the appropriate care required for a particular patient. At all times, physicians, nurses and other healthcare providers must exercise their independent clinical judgment, based on their knowledge, training and experience, taking into account the specific facts and circumstances of each patient, when deciding on the appropriate course of investigation and/or treatment to recommend in a particular clinical situation.

CHEO has made every effort to ensure that the information contained on this website is as current and accurate as possible. However, changes can occur due to ongoing research and the constant influx of new information. Where possible, hospitals and healthcare practitioners should verify the information before acting on it.

Reliance on any information in this website is at the user's own risk. CHEO is not responsible or liable for any harm, loss or other consequences from the use or misuse of the information on this website.